Serena Williams and the coming reckoning with GLP-1s and performance enhancement

Key Points:

• Serena Williams has made a comeback to professional tennis, winning a doubles match at the Queen’s grass-court tournament in London alongside Canadian Victoria Mboko, signaling a potential return to competitive play this summer.
• Williams revealed last year that she has been using GLP-1 drugs, specifically Zepbound, to manage weight and health challenges after two pregnancies, describing it as a necessary aid rather than a shortcut in her fitness journey.
• GLP-1 drugs, which help with weight loss by reducing appetite, are currently monitored but not banned by the World Anti-Doping Agency (WADA), though there is ongoing debate about their potential as performance-enhancing substances.
• The use of GLP-1 drugs raises complex issues in sports doping discussions, as they can cause both fat and muscle loss, and WADA is considering whether to classify weight management drugs more strictly, particularly for weight-sensitive sports.
• Williams’ return highlights the evolving conversation around new medical treatments in athletics, with WADA monitoring usage patterns and pharmaceutical companies supporting regulated use within approved medical guidelines.